Elkfork Partners’s Esperion Therapeutics ESPR Stock Holding History

Elkfork Partners’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$411K	Sell	11,220 -102	-0.9%	-$4.04K	0.01%	644
2019 Q2	$527K	Sell	11,322 -2,958	-21%	-$139K	0.01%	564
2019 Q1	$573K	Buy	14,280 +442	+3%	+$19.8K	0.01%	524
2018 Q4	$636K	Sell	13,838 -2,822	-17%	-$136K	0.02%	456
2018 Q3	$739K	Buy	16,660 +14,450	+654%	+$663K	0.02%	466
2018 Q2	$87K	Sell	2,210 -19,244	-90%	-$972K	﹤0.01%	944
2018 Q1	$1.55M	Buy	21,454 +16,252	+312%	+$1.19M	0.04%	262
2017 Q4	$342K	Sell	5,202 -3,774	-42%	-$203K	0.01%	647
2017 Q3	$450K	Sell	8,976 -1,088	-11%	-$52.5K	0.01%	514
2017 Q2	$466K	Sell	10,064 -3,400	-25%	-$125K	0.01%	513
2017 Q1	$475K	Hold	13,464	–	–	0.01%	468
2016 Q4	$169K	Buy	+13,464	New	+$160K	0.01%	604

Other funds holding ESPR

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Elkfork Partners's ESPR Position: Q3 2019 in Review

Elkfork Partners reduced its Esperion Therapeutics (ESPR) stake by 0.9% in Q3 2019, selling an estimated $4.04K and leaving 11,220 shares worth $411K. The position accounts for 0.01% of the portfolio, ranked #644.

Elkfork Partners first reported a position in ESPR in Q4 2016 and has held it in 12 quarters since. The position peaked at $1.55M in Q1 2018. 152 funds tracked by Wall St. Rank hold ESPR as of Q3 2019.

Elkfork Partners held 11,220 shares of Esperion Therapeutics worth $411K as of Q3 2019.
Elkfork Partners sold 102 Esperion Therapeutics shares in Q3 2019, an estimated $4.04K.
Esperion Therapeutics made up 0.01% of Elkfork Partners's portfolio in Q3 2019, its #644 holding.
Elkfork Partners first reported a position in Esperion Therapeutics in Q4 2016 and has held it in 12 quarters since.
Elkfork Partners's Esperion Therapeutics position peaked at $1.55M in Q1 2018.
152 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2019.

Based on Elkfork Partners's 13F filing for Q3 2019, filed 14 Nov 2019.